biotech · Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · CUE
Cue Biopharma
Cue Biopharma patent portfolio — 30 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2014
- Employees
- 37
- Programs
- 5
- Drugs
- 0
- Patents
- 30
Cue Biopharma patents
30 pharmaceutical patents indexed for Cue Biopharma. 0 expire within 24 months.
Cue Biopharma has 30 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12421287
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12257311
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 12180258
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12152061
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12145973
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12029782
MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
granted -
US 12006348
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
granted -
US 11993641
Methods for modulating an immune response
granted -
US 11987610
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11958893
Methods for modulating an immune response
granted -
US 11905320
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11878062
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 11851471
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11851467
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11767355
Methods for modulating an immune response
granted -
US 11739133
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11708400
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11702461
T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
granted -
US 11692018
TGF-β polypeptides
granted -
US 11530248
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11505591
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11505588
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11479595
Methods for modulating an immune response
granted -
US 11401314
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11377478
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11370821
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11117945
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11104712
Methods for modulating an immune response
granted -
US 10927161
Methods for modulating an immune response
granted -
US 10927158
T-cell modulatory multimeric polypeptides and methods of use thereof
granted
Frequently asked questions
How many patents does Cue Biopharma have?
30 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Cue Biopharma patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.